170 related articles for article (PubMed ID: 31178279)
21. What are the factors associated with short prostate specific antigen doubling time after radical prostatectomy? A report from the SEARCH database group.
Teeter AE; Bañez LL; Presti JC; Aronson WJ; Terris MK; Kane CJ; Amling CL; Freedland SJ;
J Urol; 2008 Nov; 180(5):1980-4; discussion 1985. PubMed ID: 18801519
[TBL] [Abstract][Full Text] [Related]
22. Prediction of pathologic stage and postprostatectomy disease recurrence by DNA ploidy analysis of initial needle biopsy specimens of prostate cancer.
Ross JS; Figge H; Bui HX; del Rosario AD; Jennings TA; Rifkin MD; Fisher HA
Cancer; 1994 Nov; 74(10):2811-8. PubMed ID: 7954242
[TBL] [Abstract][Full Text] [Related]
23. Clinical, Pathological and Oncologic Findings of Radical Prostatectomy with Extraprostatic Extension Diagnosed on Preoperative Prostate Biopsy.
Faisal FA; Tosoian JJ; Han M; Macura KJ; Pavlovich CP; Lotan TL
J Urol; 2019 May; 201(5):937-942. PubMed ID: 30414957
[TBL] [Abstract][Full Text] [Related]
24. Tissue microarray analysis of hMSH2 expression predicts outcome in men with prostate cancer.
Prtilo A; Leach FS; Markwalder R; Kappeler A; Burkhard FC; Cecchini MG; Studer UE; Thalmann GN
J Urol; 2005 Nov; 174(5):1814-8; discussion 1818. PubMed ID: 16217293
[TBL] [Abstract][Full Text] [Related]
25. Prognostic relevance of tripartite motif containing 24 expression in colorectal cancer.
Wang FQ; Han Y; Yao W; Yu J
Pathol Res Pract; 2017 Oct; 213(10):1271-1275. PubMed ID: 28916426
[TBL] [Abstract][Full Text] [Related]
26. SARIFA as a new histopathological biomarker is associated with adverse clinicopathological characteristics, tumor-promoting fatty-acid metabolism, and might predict a metastatic pattern in pT3a prostate cancer.
Enke JS; Groß M; Grosser B; Sipos E; Steinestel J; Löhr P; Waidhauser J; Lapa C; Märkl B; Reitsam NG
BMC Cancer; 2024 Jan; 24(1):65. PubMed ID: 38216952
[TBL] [Abstract][Full Text] [Related]
27. A prospective multicentre phase III validation study of AZGP1 as a biomarker in localized prostate cancer.
Zhang AY; Grogan JS; Mahon KL; Rasiah K; Sved P; Eisinger DR; Boulas J; Vasilaris A; Henshall SM; Stricker PD; Kench JG; Horvath LG
Ann Oncol; 2017 Aug; 28(8):1903-1909. PubMed ID: 28486686
[TBL] [Abstract][Full Text] [Related]
28. Impact of the EpCAM expression on biochemical recurrence-free survival in clinically localized prostate cancer.
Benko G; Spajić B; Krušlin B; Tomas D
Urol Oncol; 2013 May; 31(4):468-74. PubMed ID: 21514185
[TBL] [Abstract][Full Text] [Related]
29. PITX2 DNA Methylation as Biomarker for Individualized Risk Assessment of Prostate Cancer in Core Biopsies.
Uhl B; Gevensleben H; Tolkach Y; Sailer V; Majores M; Jung M; Meller S; Stein J; Ellinger J; Dietrich D; Kristiansen G
J Mol Diagn; 2017 Jan; 19(1):107-114. PubMed ID: 27939865
[TBL] [Abstract][Full Text] [Related]
30. Evaluation of ERG and SPINK1 by Immunohistochemical Staining and Clinicopathological Outcomes in a Multi-Institutional Radical Prostatectomy Cohort of 1067 Patients.
Brooks JD; Wei W; Hawley S; Auman H; Newcomb L; Boyer H; Fazli L; Simko J; Hurtado-Coll A; Troyer DA; Carroll PR; Gleave M; Lance R; Lin DW; Nelson PS; Thompson IM; True LD; Feng Z; McKenney JK
PLoS One; 2015; 10(7):e0132343. PubMed ID: 26172920
[TBL] [Abstract][Full Text] [Related]
31. A TMEFF2-regulated cell cycle derived gene signature is prognostic of recurrence risk in prostate cancer.
Georgescu C; Corbin JM; Thibivilliers S; Webb ZD; Zhao YD; Koster J; Fung KM; Asch AS; Wren JD; Ruiz-Echevarría MJ
BMC Cancer; 2019 May; 19(1):423. PubMed ID: 31060542
[TBL] [Abstract][Full Text] [Related]
32. High BIRC7 Expression Might Be an Independent Prognostic Indicator of Poor Recurrence-Free Survival in Patients With Prostate Cancer.
Yang Y; Sun P; Xu W; Xia W
Technol Cancer Res Treat; 2018 Jan; 17():1533033818809694. PubMed ID: 30376767
[TBL] [Abstract][Full Text] [Related]
33. External beam radiotherapy versus radical prostatectomy for clinical stage T1-2 prostate cancer: therapeutic implications of stratification by pretreatment PSA levels and biopsy Gleason scores.
Kupelian P; Katcher J; Levin H; Zippe C; Suh J; Macklis R; Klein E
Cancer J Sci Am; 1997; 3(2):78-87. PubMed ID: 9099457
[TBL] [Abstract][Full Text] [Related]
34. Expression of RANKL/RANK/OPG in primary and metastatic human prostate cancer as markers of disease stage and functional regulation.
Chen G; Sircar K; Aprikian A; Potti A; Goltzman D; Rabbani SA
Cancer; 2006 Jul; 107(2):289-98. PubMed ID: 16752412
[TBL] [Abstract][Full Text] [Related]
35. Validation of the prognostic value of NF-κB p65 in prostate cancer: A retrospective study using a large multi-institutional cohort of the Canadian Prostate Cancer Biomarker Network.
Grosset AA; Ouellet V; Caron C; Fragoso G; Barrès V; Delvoye N; Latour M; Aprikian A; Bergeron A; Chevalier S; Fazli L; Fleshner N; Gleave M; Karakiewicz P; Lacombe L; Lattouf JB; van der Kwast T; Trudel D; Mes-Masson AM; Saad F;
PLoS Med; 2019 Jul; 16(7):e1002847. PubMed ID: 31265453
[TBL] [Abstract][Full Text] [Related]
36. Up-regulation of POM121 is linked to prostate cancer aggressiveness and serves as a prognostic biomarker.
Becker F; Offermann A; Roesch MC; Joerg V; Roth D; Lubczyk V; Kuefer R; Sailer V; Kirfel J; Merseburger AS; Perner S
Urol Oncol; 2022 Aug; 40(8):380.e11-380.e18. PubMed ID: 35725938
[TBL] [Abstract][Full Text] [Related]
37. PD-L1 Expression and CD8
Petitprez F; Fossati N; Vano Y; Freschi M; Becht E; Lucianò R; Calderaro J; Guédet T; Lacroix L; Rancoita PMV; Montorsi F; Fridman WH; Sautès-Fridman C; Briganti A; Doglioni C; Bellone M
Eur Urol Focus; 2019 Mar; 5(2):192-196. PubMed ID: 28753812
[TBL] [Abstract][Full Text] [Related]
38. Factors affecting recurrence rates after prostatectomy or radiotherapy in localized prostate carcinoma patients with biopsy Gleason score 8 or above.
Kupelian PA; Buchsbaum JC; Elshaikh M; Reddy CA; Zippe C; Klein EA
Cancer; 2002 Dec; 95(11):2302-7. PubMed ID: 12436435
[TBL] [Abstract][Full Text] [Related]
39. Validation of the Decipher Test for Predicting Distant Metastatic Recurrence in Men with High-risk Nonmetastatic Prostate Cancer 10 Years After Surgery.
Van den Broeck T; Moris L; Gevaert T; Tosco L; Smeets E; Fishbane N; Liu Y; Helsen C; Margrave J; Buerki C; Davicioni E; Van Poppel H; Everaerts W; Weinmann S; Den R; Davis J; Schaeffer E; Karnes RJ; Claessens F; Joniau S
Eur Urol Oncol; 2019 Sep; 2(5):589-596. PubMed ID: 31411980
[TBL] [Abstract][Full Text] [Related]
40. A five-microRNA model (pCaP) for predicting prostate cancer aggressiveness using cell-free urine.
Fredsøe J; Rasmussen AKI; Mouritzen P; Borre M; Ørntoft T; Sørensen KD
Int J Cancer; 2019 Nov; 145(9):2558-2567. PubMed ID: 30903800
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
